SCYNEXIS, Inc.
SCYXHealthcare|Medical - Pharmaceuticals|US
$3.50
+0.20 (+6.06%)
Tangible Book / Share
$4.99
Cash / Share
$3.98
Financials
Financial Snapshot
Market Cap
$22.0M
Enterprise Value
$15.6M
Revenue (TTM)
$18.9M
Net Income (TTM)
-$10.1M
Cash & Investments
$47.2M
Net Cash
$45.3M
Free Cash Flow (TTM)
-$12.1M
Operating CF (TTM)
-$12.1M
Debt/Equity
0.03
Cash Runway & Burn Rate
Cash on Hand
$47.2M
Quarterly Burn
$3.0M
Monthly Burn
$1.0M
Est. Runway
~15.7 quarters
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Investments | $58.6M | $43.9M | $44.2M | $48.4M | $93.0M | $104.5M | $73.5M | $74.4M | $59.3M | $21.3M | $47.2M | |
| Operating Cash Flow | -$29.4M | -$24.6M | -$28.3M | -$38.1M | -$49.4M | -$54.6M | -$79.9M | $60.2M | -$24.0M | -$5.3M | -$12.1M | |
| Free Cash Flow | -$29.4M | -$24.6M | -$28.9M | -$38.1M | -$49.4M | -$55.7M | -$79.9M | $60.2M | -$24.0M | -$5.3M | -$12.1M | |
| Capital Expenditure | -$27.0K | -$2.0K | -$565.0K | $0.00 | -$4.0K | -$1.2M | -$9.0K | $0.00 | $0.00 | $0.00 | $0.00 | |
| Financing Cash Flow | $40.5M | $10.0M | $29.4M | $42.3M | $94.0M | $67.1M | $48.6M | -$36.7M | -$139.0K | -$14.2M | $36.8M |
R&D Spending
R&D (TTM)
$27.0M
R&D Intensity
142.9%
R&D Growth vs Prior
+21.1%
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $257.0K | $257.0K | $257.0K | $121.0K | $0.00 | $13.2M | $5.1M | $140.1M | $3.7M | $20.6M | $18.9M | |
| R&D Expense | $20.1M | $18.3M | $21.6M | $38.4M | $36.5M | $23.8M | $27.3M | $30.9M | $26.4M | $22.3M | $27.0M | |
| R&D % of Revenue | 7811.7% | 7130.7% | 8389.1% | 31730.6% | — | 180.6% | 535.4% | 22.1% | 704.9% | 108.2% | 142.9% | |
| SG&A | $8.0M | $8.3M | $8.7M | $10.6M | $14.3M | $49.9M | $63.0M | $20.9M | $14.5M | $14.4M | $15.8M |
Income Statement
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $257.0K | $257.0K | $257.0K | $121.0K | $0.00 | $13.2M | $5.1M | $140.1M | $3.7M | $20.6M | $18.9M | |
| Cost of Revenue | $0.00 | $0.00 | $0.00 | $0.00 | $303.0K | $312.0K | $628.0K | $15.6M | $0.00 | $0.00 | $0.00 | |
| Gross Profit | $257.0K | $257.0K | $257.0K | $121.0K | -$303.0K | $12.9M | $4.5M | $124.5M | $3.7M | $20.6M | $18.9M | |
| R&D | $20.1M | $18.3M | $21.6M | $38.4M | $36.5M | $23.8M | $27.3M | $30.9M | $26.4M | $22.3M | $27.0M | |
| SG&A | $8.0M | $8.3M | $8.7M | $10.6M | $14.3M | $49.9M | $63.0M | $20.9M | $14.5M | $14.4M | $15.8M | |
| Operating Income | -$27.8M | -$26.3M | -$30.0M | -$48.9M | -$51.1M | -$60.8M | -$85.8M | $72.7M | -$37.1M | -$16.1M | -$24.0M | |
| Interest Expense | $451.0K | $1.9M | $2.1M | $2.2M | $1.2M | $4.0M | $6.8M | $6.1M | $2.6M | $173.0K | $0.00 | |
| Pretax Income | -$30.0M | -$25.1M | -$19.2M | -$53.7M | -$58.3M | -$36.0M | -$67.5M | $67.2M | -$21.1M | -$8.6M | -$10.1M | |
| Net Income | -$30.0M | -$25.1M | -$12.5M | -$53.7M | -$55.2M | -$32.9M | -$62.8M | $67.0M | -$21.3M | -$8.6M | -$10.1M | |
| EPS (Diluted) | -126.04 | -75.20 | -22.73 | -76.62 | -41.18 | -9.97 | -11.79 | 11.08 | -3.51 | -1.38 | -1.17 | |
| EBITDA | -$29.5M | -$23.2M | -$17.1M | -$51.4M | -$55.8M | -$32.9M | -$60.1M | $70.9M | -$18.6M | -$8.1M | -$11.4M | |
| Shares Out. (M) | 0.24 | 0.33 | 0.55 | 0.70 | 1.34 | 3.30 | 5.33 | 6.05 | 6.06 | 6.24 | 11.84 |
Balance Sheet
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $35.7M | $11.5M | $11.4M | $41.9M | $93.0M | $104.5M | $45.8M | $34.0M | $16.1M | $21.3M | $8.2M | |
| Short-Term Investments | $22.9M | $32.4M | $32.7M | $6.5M | $0.00 | $0.00 | $27.7M | $40.3M | $43.2M | $0.00 | $38.9M | |
| Total Current Assets | $59.3M | $45.0M | $51.5M | $52.4M | $98.2M | $109.4M | $79.1M | $102.1M | $72.2M | $40.4M | $50.4M | |
| Total Assets | $59.8M | $45.9M | $53.2M | $57.2M | $102.5M | $119.8M | $87.8M | $128.4M | $90.6M | $59.0M | $68.0M | |
| Total Current Liabilities | $3.7M | $10.1M | $5.9M | $11.0M | $26.4M | $13.6M | $17.6M | $16.3M | $24.1M | $5.7M | $6.7M | |
| Long-Term Debt | $14.3M | $10.3M | $15.1M | $11.5M | $16.5M | $40.4M | $45.4M | $12.2M | $0.00 | $0.00 | $0.00 | |
| Total Liabilities | $25.0M | $24.4M | $21.9M | $44.3M | $79.8M | $78.6M | $84.6M | $55.5M | $35.6M | $9.7M | $8.9M | |
| Stockholders' Equity | $34.8M | $21.4M | $31.2M | $12.9M | $22.8M | $41.3M | $3.2M | $73.0M | $55.1M | $49.4M | $59.0M | |
| Retained Earnings | -$180.1M | -$205.3M | -$217.7M | -$271.4M | -$326.6M | -$359.5M | -$422.3M | -$355.2M | -$376.5M | -$385.1M | -$407.5M |
Cash Flow Statement
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -$29.4M | -$24.6M | -$28.3M | -$38.1M | -$49.4M | -$54.6M | -$79.9M | $60.2M | -$24.0M | -$5.3M | -$12.1M | |
| Capital Expenditure | -$27.0K | -$2.0K | -$565.0K | $0.00 | -$4.0K | -$1.2M | -$9.0K | $0.00 | $0.00 | $0.00 | $0.00 | |
| Free Cash Flow | -$29.4M | -$24.6M | -$28.9M | -$38.1M | -$49.4M | -$55.7M | -$79.9M | $60.2M | -$24.0M | -$5.3M | -$12.1M | |
| Investing Cash Flow | -$22.5M | -$9.6M | -$803.0K | $26.2M | $6.5M | -$1.2M | -$27.4M | -$34.9M | $6.2M | $24.3M | -$31.3M | |
| Financing Cash Flow | $40.5M | $10.0M | $29.4M | $42.3M | $94.0M | $67.1M | $48.6M | -$36.7M | -$139.0K | -$14.2M | $36.8M | |
| Issuance of Stock | $28.1M | $10.3M | $31.7M | $43.5M | $90.6M | $38.6M | $47.2M | $18.0K | -$139.0K | -$170.0K | $39.8M | |
| Repurchase of Stock | $0.00 | $0.00 | $0.00 | $0.00 | -$208.0K | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | -$2.5M | |
| Net Debt Issuance | $15.0M | $0.00 | $0.00 | $27.0K | $9.5M | $30.0M | $5.0M | -$36.6M | $0.00 | -$14.0M | $0.00 | |
| Stock Based Comp. | $1.2M | $1.7M | $1.8M | $1.8M | $2.2M | $2.1M | $3.7M | $2.6M | $3.3M | $2.9M | $2.4M | |
| Net Change in Cash | -$11.3M | -$24.2M | $298.0K | $30.4M | $51.1M | $11.4M | -$58.7M | -$11.4M | -$18.0M | $4.9M | -$6.5M |
Dilution Tracker
Shares outstanding grew 365.8% over 5 years — significant dilution
Shares Outstanding
6M
5-Year Share Growth
+365.8%
Stock Issuance (TTM)
$39.8M
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Shares Out. (M) | 0.24 | 0.33 | 0.55 | 0.70 | 1.34 | 3.30 | 5.33 | 6.05 | 6.06 | 6.24 | 11.84 | |
| Change vs Prior % | — | 40.5% | 64.1% | 27.8% | 91.2% | 146.1% | 61.5% | 13.6% | 0.3% | 2.9% | 89.7% | |
| Stock Issuance | $28.1M | $10.3M | $31.7M | $43.5M | $90.6M | $38.6M | $47.2M | $18.0K | -$139.0K | -$170.0K | $39.8M | |
| Stock Repurchase | $0.00 | $0.00 | $0.00 | $0.00 | -$208.0K | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | -$2.5M | |
| Stock Based Comp. | $1.2M | $1.7M | $1.8M | $1.8M | $2.2M | $2.1M | $3.7M | $2.6M | $3.3M | $2.9M | $2.4M |
Margins & Profitability
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin % | 100.0% | 100.0% | 100.0% | 100.0% | — | 97.6% | 87.7% | 88.9% | 100.0% | 100.0% | 100.0% | |
| Operating Margin % | -10823.7% | -10241.2% | -11666.5% | -40430.6% | — | -462.2% | -1684.5% | 51.9% | -990.8% | -78.0% | -126.9% | |
| Net Margin % | -11668.9% | -9751.0% | -4851.4% | -44388.4% | — | -249.7% | -1233.7% | 47.8% | -568.3% | -41.8% | -53.5% | |
| EBITDA Margin % | -11483.3% | -9013.2% | -6652.5% | -42514.0% | — | -250.1% | -1180.8% | 50.6% | -496.1% | -39.4% | -60.4% | |
| FCF Margin % | -11431.9% | -9555.6% | -11240.5% | -31503.3% | — | -423.4% | -1569.3% | 42.9% | -640.9% | -25.6% | -63.8% | |
| ROE % | -86.1% | -117.0% | -39.9% | -416.5% | -242.5% | -79.7% | -1942.7% | 91.9% | -38.7% | -17.4% | -18.7% | |
| ROA % | -50.2% | -54.7% | -23.4% | -94.0% | -53.8% | -27.4% | -71.5% | 52.2% | -23.5% | -14.6% | -14.9% | |
| ROIC % | -49.6% | -65.7% | -41.2% | -105.9% | -63.5% | -52.3% | -113.2% | 64.5% | -46.0% | -29.9% | -38.7% | |
| R&D / Revenue % | 7811.7% | 7130.7% | 8389.1% | 31730.6% | — | 180.6% | 535.4% | 22.1% | 704.9% | 108.2% | 142.9% |
Growth (Year over Year)
Fiscal years. Rising share count growth means dilution.
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0.0% | 0.0% | 0.0% | -52.9% | -100.0% | 0.0% | -61.3% | 2652.7% | -97.3% | 449.9% | |
| Gross Profit | 0.0% | 0.0% | 0.0% | -52.9% | -350.4% | 4341.3% | -65.3% | 2690.0% | -97.0% | 449.9% | |
| Operating Income | 1.9% | 5.4% | -13.9% | -63.2% | -4.6% | -18.9% | -41.0% | 184.7% | -151.1% | 56.7% | |
| Net Income | 8.1% | 16.4% | 50.2% | -330.8% | -2.7% | 40.4% | -91.1% | 206.7% | -131.8% | 59.6% | |
| EPS (Diluted) | 41.1% | 40.3% | 69.8% | -237.1% | 46.3% | 75.8% | -18.3% | 194.0% | -131.7% | 60.7% | |
| Operating Cash Flow | -19.6% | 16.3% | -15.3% | -34.6% | -29.5% | -10.5% | -46.4% | 175.3% | -139.9% | 78.0% | |
| Free Cash Flow | -16.9% | 16.4% | -17.6% | -32.0% | -29.5% | -12.9% | -43.4% | 175.3% | -139.9% | 78.0% | |
| R&D Expense | 22.1% | -8.7% | 17.6% | 78.1% | -4.9% | -34.9% | 14.7% | 13.5% | -14.6% | -15.6% | |
| SG&A Expense | -34.3% | 3.2% | 5.2% | 22.7% | 34.5% | 248.5% | 26.1% | -66.8% | -30.9% | -0.4% | |
| Total Assets | 21.3% | -23.3% | 16.0% | 7.5% | 79.4% | 16.9% | -26.7% | 46.2% | -29.4% | -34.9% | |
| Book Value / Share | -47.0% | -56.2% | -11.1% | -67.7% | -7.7% | -26.3% | -95.1% | 1909.7% | -25.5% | -12.9% | |
| Debt | 0.0% | 2.8% | 2.9% | -1.3% | 33.3% | 119.9% | 11.4% | -69.0% | 7.9% | -86.6% | |
| Diluted Shares | 56.5% | 40.5% | 64.1% | 27.8% | 91.2% | 146.1% | 61.5% | 13.6% | 0.3% | 2.9% |
Valuation
P/E (TTM)At Loss
P/S1.17
10Y Low / Med / High0.76 / 15.67 / 421.77
P/B0.70
10Y Low / Med / High0.64 / 2.90 / 20.56
EV/EBITDAAt Loss
EV/Revenue0.83
10Y Low / Med / High0.61 / 15.73 / 253.83
P/FCFAt Loss
Intrinsic Value Models (per share)
Tangible Book / Share
$4.99
Net Current Assets / Share
$6.59
Graham Net-Net
$3.23
Cash / Share
$3.98
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| P/E Ratio | -2.02 | -2.47 | -1.70 | -0.95 | -1.49 | -4.89 | -1.06 | 1.59 | -2.76 | -3.67 | -2.99 | |
| P/S Ratio | 236.27 | 241.45 | 82.30 | 421.77 | 0.00 | 12.23 | 13.06 | 0.76 | 15.67 | 1.53 | 1.17 | |
| P/B Ratio | 1.74 | 2.90 | 0.68 | 3.96 | 3.60 | 3.90 | 20.56 | 1.46 | 1.07 | 0.64 | 0.70 | |
| EV/EBITDA | -1.33 | -2.82 | -1.45 | -0.47 | -0.16 | -3.04 | -1.15 | 1.24 | -3.17 | -1.54 | -1.37 | |
| EV/Revenue | 152.99 | 253.83 | 96.48 | 198.33 | 0.00 | 7.60 | 13.60 | 0.63 | 15.73 | 0.61 | 0.83 |
Analyst Estimates & Quality
Altman Z-Score
-6.42
Distress
Piotroski F-Score
2
Weak
Forward Estimates (consensus)
| Metric | FY2026 | FY2027 | FY2028 |
|---|---|---|---|
| Revenue | $619.5K | $1.3M | $10.8M |
| Net Income | -$30.6M | -$16.1M | -$22.5M |
| EPS | $-2.91 | $-2.31 | $-2.09 |
| # Analysts (EPS) | 1 | 1 | 3 |
Revenue Segments
By Product
| Segment | 2019 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| License And Service | $100.0K | $12.1M | — | — | — | — |
| Product | — | $1.1M | $5.0M | $1.0M | — | $1.4M |
| License and Service | — | — | $103.0K | $139.1M | $3.7M | $19.2M |
By Geography
| Segment | 2014 | 2015 | 2016 |
|---|---|---|---|
| Europe | $1.2M | $477.0K | — |
| Other Non-US | $1.4M | $257.0K | $257.0K |
| UNITED STATES | $16.4M | $6.9M | — |